1,041 reports of this reaction
6.2% of all BLINATUMOMAB reports
#2 most reported adverse reaction
ACUTE LYMPHOCYTIC LEUKAEMIA RECURRENT is the #2 most commonly reported adverse reaction for BLINATUMOMAB, manufactured by Amgen, Inc. There are 1,041 FDA adverse event reports linking BLINATUMOMAB to ACUTE LYMPHOCYTIC LEUKAEMIA RECURRENT. This represents approximately 6.2% of all 16,815 adverse event reports for this drug.
Patients taking BLINATUMOMAB who experience acute lymphocytic leukaemia recurrent should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ACUTE LYMPHOCYTIC LEUKAEMIA RECURRENT is moderately reported among BLINATUMOMAB users, representing a notable but not dominant share of adverse events.
In addition to acute lymphocytic leukaemia recurrent, the following adverse reactions have been reported for BLINATUMOMAB:
ACUTE LYMPHOCYTIC LEUKAEMIA RECURRENT has been reported as an adverse event in 1,041 FDA reports for BLINATUMOMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
ACUTE LYMPHOCYTIC LEUKAEMIA RECURRENT accounts for approximately 6.2% of all adverse event reports for BLINATUMOMAB, making it one of the most commonly reported side effect.
If you experience acute lymphocytic leukaemia recurrent while taking BLINATUMOMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.